Efficacy and Safety of Brolucizumab, Aflibercept, and Ranibizumab for the Treatment of Patients with Visual Impairment Due to Diabetic Macular Oedema: A Systematic Review and Network Meta-Analysis

• Published in: Diabetes therapy Vol. 14; no. 7; pp. 1193 - 1216
• Main Authors: Sydnor, Shelby, Chatterjee, Swarnendu, Cooney, Philip, Kaur, Simarjeet, Macmillan, Tom, Stewart, Daisy, Munro, Isobel, Bandeiras, Cátia, Paine, Abby, Felizzi, Federico
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.07.2023; Springer; Springer Nature B.V
• Subjects: Cardiology; Complications and side effects; Diabetes; Diabetic retinopathy; Drug therapy; Edema; Endocrinology; Evaluation; Eye diseases; Internal Medicine; Literature reviews; Medicine; Medicine & Public Health; Monoclonal antibodies; Original Research; Pharmaceutical research; Vascular endothelial growth factor; Vision disorders; Visual impairment; United Kingdom; Best-corrected visual acuity; Diabetic retinopathy; Network meta-analysis; Retinal thickness; Diabetic macular oedema; Visual impairment; Ranibizumab; Anti-VEGF; Aflibercept; Brolucizumab

Introduction Key clinical guidelines recommend anti-vascular endothelial growth factor (VEGF) therapy as first-line treatment for visual impairment due to diabetic macular oedema (DMO). A systematic literature review (SLR) and network meta-analysis (NMA) were conducted comparing the relative efficac...